Cost-utility analysis of vaccination against HPV in Israel.
Using WHO-CHOICE methodology, we calculated cost-utility ratios for various interventions (PAP smear, HPV-DNA testing, VIA and vaccination against HPV) at various frequencies to reduce the burden of cervical cancer and condyloma (in the case of the HPV vaccination) in Israel, which has a low prevalence of cervical cancer. Assuming non-waning efficacy, HPV vaccinations will become cost-effective, very cost-effective and cost saving when the cost per dose falls below $96.85, $50.42 and $27.20, respectively. Attempts should be made to raise compliancy with PAP smears from the current opportunistic 12.2-20.0% per annum either before and/or after the vaccination is introduced.
Ginsberg
Gary Michael
GM
Medical Technology Assessment Sector, Ministry of Health, Ben Tbai 2, San Simone, Jerusalem, Israel. gary.ginsberg@moh.health.gov.il
Fisher
Menachem
M
Ben-Shahar
Inbar
I
Bornstein
Jacob
J
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000276:immunology*; D002648:Child; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007557:Israel; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D008954:Models, Biological; D030361:Papillomavirus Infections / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000276:immunology*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics*
D053918:Papillomavirus Vaccines